Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log-in |  Register |  Search

Back to the forum  Query: 2018-05-21 11:18 CEST (UTC+2h)
 
rajasekharkakarla
Junior

India,
2018-05-03 12:28

Posting: # 18753
Views: 392
 

 Steady State design [Design Issues]

Dear Sir/Madam,

I have some doubts in designing study state protocols.

Example: Tamsulosin

how to fix number of days to dosing

how to fix number of doses per day

My regular practice is if label/smpc states achievement of steady-state concentrations by the fifth day of once-a-day dosing for Tamsulosin, i will design the study state protocol with once a day dosing for five days. but i want to know the exact scientific rationale behind this.

please help me...

Regards,
Rajasekhar


Edit: Category changed; see also this post #1. [Helmut]
Helmut
Hero
Homepage
Vienna, Austria,
2018-05-03 14:12

@ rajasekharkakarla
Posting: # 18754
Views: 325
 

 5–7 predominant half lives

Hi Rajasekhar,

» Example: Tamsulosin
» how to fix number of days to dosing

Until (pseudo) steady state is achieved. See this post for an example of linear PK.
Which regulation are you “targeting”? For the FDA a multiple dose study is not required. Since the SmPC recommends intake after breakfast, according to the EMA’s GL the multiple dose study has to be performed in fed state.

» how to fix number of doses per day

According to the posology of the reference (for tamsulosin OAD after breakfast).

» My regular practice is if label/smpc states achievement of steady-state concentrations by the fifth day of once-a-day dosing for Tamsulosin, i will design the study state protocol with once a day dosing for five days.

Fine but copy/paste ≠ science. :-D

» […] i want to know the exact scientific rationale behind this.

Kudos. Steady state is practically reached after 5–7 predominant half lives (96.9–99.2% of theoretical steady state). Note that Flomax® is a CR-formulation (flip-flop PK, where ka < ke). Whereas the elimination half life (after IV or IR) is ~6–7 hours, the apparent one of the CR is substantially prolonged (see the FDA’s NDA approval; page 217 of the PDF).

For drugs with nonlinear PK (e.g., saturation of metabolizing enzymes, auto-induction or -inhibition) it is complicated. Consult with a pharmacokineticist.

[image]Cheers,
Helmut Schütz 
[image]

The quality of responses received is directly proportional to the quality of the question asked. ☼
Science Quotes
Back to the forum Activity
 Thread view
Bioequivalence and Bioavailability Forum | Admin contact
18,269 posts in 3,882 threads, 1,161 registered users;
20 users online (1 registered, 19 guests).

Science is wonderfully equipped to answer the question “How?”
but it gets terribly confused when you ask the question “Why?”    Erwin Chargaff

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
XHTML/CSS RSS Feed